Staging Classification and Stratification of Pancreatic Cancer for Clinical Practice

2021 ◽  
pp. 433-442
Author(s):  
Akhil Chawla ◽  
Andrew J. Aguirre
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Staging Classification

scholarly journals Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1986
Author(s):  
Victoria Heredia-Soto ◽  
Nuria Rodríguez-Salas ◽  
Jaime Feliu
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Early Diagnosis ◽  
Minimally Invasive ◽  
Liquid Biopsy ◽  
Genetic Material ◽  
Current Status ◽  
Ductal Adenocarcinoma ◽  
Disease Monitoring ◽  
Global Status

Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for detecting and monitoring PDAC.

scholarly journals The role of imaging in the clinical practice of radiation oncology for pancreatic cancer

2017 ◽  
Vol 43 (2) ◽  
pp. 393-403 ◽  
Author(s):  
Eugene J. Koay ◽  
William Hall ◽  
Peter C. Park ◽  
Beth Erickson ◽  
Joseph M. Herman
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Radiation Oncology

scholarly journals Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer

Pancreas ◽  
2017 ◽  
Vol 46 (8) ◽  
pp. 967-972 ◽  
Author(s):  
Lihua He ◽  
Lizhi Niu ◽  
Nikolai N. Korpan ◽  
Sajio Sumida ◽  
Yueyong Xiao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines

scholarly journals Standard Clinical Practice of Folfirinox in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: A Canadian Registry

2014 ◽  
Vol 25 ◽  
pp. ii49
Author(s):  
Maroun Jean ◽  
Ko Yoo-Joung ◽  
Ghafoor Akmal ◽  
Cripps Christine ◽  
Jonker Derek ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Metastatic Pancreatic Cancer ◽  
Standard Clinical Practice

scholarly journals Clinical Practice as an Engine Driving a Translational Research Program in Pancreatic Cancer

2011 ◽  
Vol 140 (5) ◽  
pp. S-1021
Author(s):  
Eugene P. Kennedy ◽  
Jonathan R. Brody ◽  
Agnes Witkiewicz ◽  
Harish Lavu ◽  
Patricia K. Sauter ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Translational Research ◽  
Research Program ◽  
Translational Research Program

Investigation of the tolerability of FOLFIRINOX in patients with unresectable advanced pancreatic cancer: Single-institution experience in Japan.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 487-487 ◽  
Author(s):  
Kouichirou Miyashita ◽  
Takashi Sekikawa ◽  
Ken Shimada ◽  
Taikan Yamamoto ◽  
Yasuhiro Kaga ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Clinical Stage ◽  
Performance Status ◽  
Objective Response ◽  
Advanced Pancreatic Cancer ◽  
Dose Intensity ◽  
Eligibility Criteria ◽  
Grade 3 ◽  
Practice Methods

487 Background: FOLFIRINOX therapy has contributed to the overall survival extension of unresectable advanced pancreatic cancer. This regimen is however associated with significant toxicity. And doing the treatment, while careful to toxicity at our institution. We investigated the tolerability of FOLFIRINOX for the treatment of unresectable advanced pancreatic cancer in clinical practice. Methods: We conducted a retrospective analysis of patients with unresectable advanced pancreatic cancer who received FOLFIRINOX between November 2012 and August 2014. FOLFIRINOX is as follows: irinotecan at 150 mg/m2; oxaliplatin at 85 mg/m2; 5-fluorouracil (5FU) at 400mg/m2 bolus, 2,400mg/m2 continuous infusion. Patients' characteristics, objective response, survival and toxicities were collected. Response were evaluated with RECIST version 1.1 and toxicities with NCI-CTCAE version 4.0. Results: 13 patients were includes (8 males and 5 females). Treatment eligibility criteria in our institution were Performance Status 0 or 1, and UGT1A1 polymorphisms were excluded. Median age was 58.6 years (41-74). Clinical stage IVa/IVb was 3/10. The mean number therapy was 7.7 (3-15) cycles. The toxicity of all grade was 100% and grade 3 was 80%. The non-hematological toxicities included nausea in 8 patients (61.5%) and anorexia in 9 (69.2%). The hematological toxicities included neutropenia in 12 patients (92.3%), of which 11 (84.6%) presented a grade 3/4 neutropenia. In patients who developed grade 3 neutropenia, the treatment of FOLFIRINOX could be continued once every three weeks (triweekly) without reducing the dose. Response rate was 38.5% (CR: 0, PR: 5, SD: 6, PD: 2) and disease control rate was 84.6%. Time to treatment failure was 175 days. Relative dose intensity was 95.0% for oxaliplatin, 88.9% for irinotecan, 81.9% for 5FU (bolus), and 95.6% for 5FU (continuous). Conclusions: In clinical practice, it is expected that FOLFIRINOX is an effective, well-tolerated regimen by reducing the dose or determining the appropriate dosing interval.

Sign in / Sign up

Export Citation Format

Share Document